Many times in Phase 1 testing primarily for toxcity, dosage etc, efficacy may express itself.. According to a company statement, thats exactly what Oncolix is claiming.
On the bright side, efficacy demonstrated in this study for Ovarian cancer for patients already treated with SOC, is very significant to note. In addition, it was low dose Prolanta as a monotherapy, without chemo. Because of this and depending upon the degree of efficacy, Oncolix becomes extremely interesting
On the dark side, the efficacy alluded to is not provided in detail or quantified. Therefore, one is left wondering why the efficacy data is not public info.
